{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:57:08Z","timestamp":1791932228566,"version":"4.3.4"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In the last French study in 2007, the incidence of hospital admissions (HAs) related to adverse drug reactions (ADRs) was 3.6%. The objective was to assess the current ADR\u2010HA incidence in France and to describe both its characteristics and preventability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective multicentre study was conducted among randomly selected French public hospital medical wards (April\u2013July 2018). Patients admitted during a week period were included. ADR\u2010HA cases were collected by the French Regional Pharmacovigilance Centres network. An independent committee validated potential cases and ADR preventability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ADR\u2010HA incidence was 8.5% (95% confidence interval [CI]: 7.6\u20139.4%), increasing with age (3.3% [95%CI: 1.8\u20135.5%]\u2009\u226416\u2009y\n                      <jats:italic>vs<\/jats:italic>\n                      . 10.6% [95%CI: 9.3\u201312.0%]\u2009\u226565\u2009y). The most common ADRs were haemorrhagic events (8.8%), haematological disorders (6.5%), acute renal failure (6.3%), fluid and electrolyte disorders (6.0%), and falls (5.2%). New drugs were involved: targeted therapies (22.8% of antineoplastics), direct oral anticoagulants (29.6% of antithrombotics) and incretin\u2010based drugs (20.0% of antidiabetics). ADRs were preventable in 16.1% of cases because the drugs involved had not been used in accordance with monographies, package leaflets or other therapeutic guidelines. The main situations of noncompliance addressed either dose or duration of use (27.9%), warning (23.2%), use precaution (18.6%) and inappropriate self\u2010medication or misuse by patients (11.6%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In France, ADR\u2010HA incidence dramatically increased over the last decade. A significant proportion was related to new pharmacological classes and considered as preventable. These findings should lead to in\u2010depth thought on preventive actions on at\u2010risk drug classes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.15510","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:38:08Z","timestamp":1661377088000},"page":"390-400","source":"Crossref","is-referenced-by-count":45,"title":["Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT)"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-0359","authenticated-orcid":false,"given":"Marie\u2010Laure","family":"Laroche","sequence":"first","affiliation":[{"name":"Regional Pharmacovigilance Centre of Limoges, Department of Pharmacology\u2010Toxicology and Pharmacovigilance CHU Limoges  Limoges France"},{"name":"UR 24134 (VieSant\u00e9\u2010 Vieillissement, Fragilit\u00e9, Pr\u00e9vention, e\u2010Sant\u00e9), IFR OMEGA HEALTH Universit\u00e9 de Limoges  Limoges France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Lille Pharmacology Department, CHU Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Rennes CHU Rennes  Rennes Francie France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-5733","authenticated-orcid":false,"given":"Marie\u2010Blanche","family":"Rabier","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Besan\u00e7on CHU Besan\u00e7on  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3571","authenticated-orcid":false,"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Cochin, Pharmacology Department AP\u2010HP. Centre \u2013 Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-5063","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Lebrun\u2010Vignes","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Piti\u00e9 and Saint Antoine Hospital APHP Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0100-4073","authenticated-orcid":false,"given":"Jean\u2010Luc","family":"Faillie","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Montpellier CHU Montpellier  Montpellier France"},{"name":"IDESP, Univ. Montpellier, INSERM  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-3178","authenticated-orcid":false,"given":"Nadine","family":"Petitpain","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre of Nancy CHRU Nancy  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7609-6972","authenticated-orcid":false,"given":"Laurence","family":"Lagarce","sequence":"additional","affiliation":[{"name":"Department of Pharmacology\u2010Toxicology and Pharmacovigilance, CHU Angers Regional Pharmacovigilance Centre of Angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2635-3360","authenticated-orcid":false,"given":"Annie\u2010Pierre","family":"Jonville\u2010Bera","sequence":"additional","affiliation":[{"name":"Regional Pharmacovigilance Centre \u2010 Centre\u2010Val de Loire Pharmacosurveillance Unit, CHRU Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the IATROSTAT study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12293"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47909"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010016\u20100444\u20107"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010015\u20100281\u20100"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010016\u20102170\u20106"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.02.029"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12088"},{"key":"e_1_2_11_9_1","unstructured":"EMA.Guideline on good pharmacovigilance practices. EMA\/876333\/2011. Available on:https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf"},{"issue":"1","key":"e_1_2_11_10_1","first-page":"S1","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2019\/20: Introduction and Other Protein Targets","volume":"176","author":"Alexander SPH","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"2","key":"e_1_2_11_11_1","first-page":"111","article-title":"Imputabilit\u00e9 des effets inattendus ou toxiques des m\u00e9dicaments. Actualisation de la m\u00e9thode utilis\u00e9e en France [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]","volume":"40","author":"B\u00e9gaud B","year":"1985","journal-title":"Therapie"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200932050\u201000006"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2022.01.003"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.29252\/beat\u2010070401"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2010.100113"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14134"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015570104121"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L037"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12106"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237022"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14362"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","unstructured":"ANSM.Rapport sur la consommation des antalgiques opio\u00efdes en France(2019). Available on:https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Antalgiques-opioides-l-ANSM-publie-un-etat-des-lieux-de-la-consommation-en-France-Point-d-Information","DOI":"10.1016\/S1773-035X(19)30282-5"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12314"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010020\u201003043\u20103"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010013\u20100114\u2010y"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12546"},{"key":"e_1_2_11_27_1","first-page":"576","article-title":"Principales \u00e9volutions de la mortalit\u00e9 par cause sur la p\u00e9riode 2000\u20102016 en France m\u00e9tropolitaine","volume":"29","author":"Boulat T","year":"2019","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2021.12.007"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15510","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15510","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T07:21:25Z","timestamp":1692429685000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/bcp.15510"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15510","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]}}}